drug-discovery

To evaluate drug-likeness and ADMET properties, you can retrieve molecular data from public APIs like ChEMBL and PubChem, then compute Ro5, Veber, TPSA, and synthetic accessibility to summarize safety signals for lead optimization.

Assessing lead optimization trade-offs involves aggregating cheminformatics data to triage molecular properties, evaluate drug-likeness metrics like QED, and summarize safety signals for data-driven scaffold decisions in medicinal chemistry workflows.

Yes, you can query ChEMBL to identify bioactive compounds and their targets, while using PubChem and OpenFDA to look up drug interactions and cross-reference safety signals for candidate molecules.

The drug discovery workflow operates using built-in Python and curl scripts to programmatically retrieve cheminformatics data from public databases, requiring no external dependencies to compute properties like MW, LogP, and HBD/HBA.

Computing Veber rules and TPSA is needed during drug-likeness assessment to evaluate oral bioavailability and permeability, helping identify viable lead compounds by filtering out molecules with poor absorption characteristics.

Limitations of using public APIs for pharmacology data retrieval include dependency on external database uptime and potential gaps in ADMET or OpenTargets coverage, requiring manual interpretation of summarized safety signals.